Oligodendrocyte lineage differentiation

Oligodendrocyte lineage differentiation refers to the developmental process by which oligodendrocyte precursor cells (OPCs) mature into functional, myelinating oligodendrocytes in the central nervous system. This multistep progression involves tightly regulated transcriptional, epigenetic, and proteomic changes orchestrated by transcription factors such as OLIG1, OLIG2, SOX10, NKX2.2, and MYRF, as well as environmental and signaling cues (e.g., mTOR pathway, planar cell polarity, autophagy). Proper differentiation is essential for CNS myelination and axonal support. Disruption of this process is implicated in various demyelinating and neurodegenerative diseases, notably multiple sclerosis. While not a molecule or receptor suitable for direct pharmacological targeting, molecules that regulate or mark these differentiation stages—such as PDGFRA, LINGO1, and the myelin transcription factors—can be, and some are under therapeutic investigation[1][2][3][4][5]. Oligodendrocyte lineage differentiation is a biological process, not a discrete molecule, receptor, or actionable drug target, and thus is_incorrect = true for use as a canonical therapeutic target entry.

Other names

Oligodendrocyte differentiationOligodendrocyte lineage progressionOL differentiation